Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 349209, 8 pages doi:10.1155/2012/349209

Research Article

Aquatic Exercise Is Effective in Improving Exercise Performance in Patients with Heart Failure and Type 2 Diabetes Mellitus

Cider Åsa,1,2 Schaufelberger Maria,3 Stibrant Sunnerhagen Katharina,1 and Andersson Bert3

- ¹ Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, The Sahlgrenska Academy, University of Gothenburg, Mailbox 455, 405 35 Gothenburg, Sweden
- ² Physiotherapy and Occupational Therapy Department, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden

Correspondence should be addressed to Cider Åsa, asa.cider@gu.se

Received 14 October 2011; Revised 22 January 2012; Accepted 23 January 2012

Academic Editor: Myeong Soo Lee

Copyright © 2012 Cider Åsa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Peak oxygen uptake (VO_{2peak}) and muscle function are more decreased in patients with a combination of chronic heart failure (CHF) and type 2 diabetes mellitus (2DM) compared to patients with only one of the conditions. Further, patients with 2DM have peripheral complications that hamper many types of conventional exercises. Aim. To evaluate the efficacy and applicability of eight-week aquatic exercise in patients with the combination of CHF and 2DM. Methods. Twenty patients (four women) with both CHF and 2DM (age 67.4 \pm 7.1, NYHA II-III) were randomly assigned to either aquatic exercise or a control group. The patients exercised for 45 minutes 3 times/week in 33–34°C, swimming pool. Results. The training programme was well tolerated. Work rate (+11.7 \pm 6.6 versus -6.4 ± 8.1 watt, P < 0.001) and VO_{2peak} (+2.1 \pm 0.8 versus -0.9 ± 1.4 mL·kg⁻¹·min⁻¹, P < 0.001) and walking capacity (P = 0.01) increased significantly in the training group. Muscle function was also significantly improved and Hba1c decreased significantly (P < 0.01) during training, while fasting glucose, insulin, c-peptide, and lipids were unchanged. Training also increased vitality measured by SF-36 significantly (P = 0.05). Conclusion. Aquatic exercise could be used to improve exercise capacity and muscle function in patients with the combination of CHF and 2DM.

1. Introduction

Up to 25% of patients with chronic heart failure (CHF) have type 2 diabetes mellitus (2DM) [1], and it could be foreseen that this combination will be increasingly common [2]. 2DM entails a markedly increased risk of developing cardiovascular diseases [3]. Further, in all types of cardiovascular disease patients with 2DM have a significantly higher rate of mortality and morbidity than patients without [4]. On the contrary, CHF results in an insulin resistance syndrome which in turn could lead to the development of 2DM [5]. Both patients with CHF and 2DM, separately or in combination, suffer from reduced physical function, with decreased oxygen uptake and poor muscle function [6, 7]. In both conditions, similar pathological consequences

are found in the skeletal muscle, such as an increased number of type II muscle fibres, low capillary density, and decreased oxidative capacity [8, 9]. Other similarities are signs of impaired endothelial function, which might be important to muscle function and physical performance [10, 11]. However, the impaired endothelial function might be corrected by exercise training [12]. The diseases do often impact negatively on activity of daily living and quality of life. These patients risk in a greater extent to develop depression and anxiety in comparison with a healthy population [13, 14]. There are consistent reports of improvement in physical performance and psychological function after aerobic and/or resistance exercise training in CHF as well as in 2DM [15, 16]. Since the prevalence of both conditions increases with age it is not unusual that patients also have other disabilities

³ Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Mailbox 100, 405 30 Gothenburg, Sweden

that further restrain physical ability. Aquatic exercise, that is, physical training in warm water, is an alternative exercise regimen, and we have recently shown positive effects of aquatic exercise in patients with CHF without 2DM [17]. To confirm the results of our previous study using aquatic exercise and to assess the efficacy of such training in patients with the combination of CHF and 2DM, this study was performed.

The hypothesis was that training in warm water would be safe and result in improvement in physical performance, muscle function, and metabolic control in patients with CHF and 2DM

Therefore the aim of this study was to investigate the effect of aquatic exercise in patients with CHF and 2DM.

2. Methods

2.1. Patients. Twenty patients (four women) with stable CHF and 2DM in NYHA class II or III, ejection fraction (EF) <50%, age above 55 years were included. Heart failure medication had to be stable for the previous three months. Exclusion criteria were peripheral artery disease, chronic pulmonary disease, status after stroke, or other disabling diseases that might interfere with the exercise protocol. The process of patient recruitment is described in Figure 1. After baseline testing, patients were randomised, using a 1:1 ratio, in a stratified according to order to 8 weeks of aquatic exercise (n = 10), or to a control period (n = 10). The patients were stratified according to age, NYHA class and gender. Baseline characteristics of the study population are given in Table 1. The study complied with the Declaration of Helsinki. The Ethics committee of Gothenburg University approved the research protocol, and informed consent was obtained from each subject. The testing procedures were repeated after eight weeks of training or control period, respectively.

2.2. Procedure. All patients performed the below given tests within 10 days before the randomisation and then during the last 10 days of the study period. Patients started on the first day with venous blood samples followed by an acquaintance test on the ergospirometer. Thereafter, questionnaires were filled out and the six-minute walk test performed. Finally patients performed on day 4–6 the maximal test on the ergospirometer and on day 8–10 the muscle tests.

2.3. Assessments

2.3.1. Exercise Capacity. Work rate and peak oxygen uptake (VO_{2peak}) were measured on an ergometer, using a ramp protocol with a 10-watt increase every minute until exhaustion. Expired gas was measured breath by breath using a V-max system (Sensor Medics, USA) as previously described [17].

2.3.2. Six-Minute Walking Test. A standardised six-minute walking test was used to assess exercise capacity related to activities of daily living. The patients were asked to walk as far as possible during six minutes on a premarked 30-meter walkway [17, 18].

Table 1: Demographic data of patients with chronic heart failure and type 2 diabetes mellitus.

Variables Training $(n = 10)$ Control $(n = 10)$ P value Age (years) 65.8 ± 5.8 69 ± 8.2 ns Sex (F/M) $2/8$ $2/8$ ns Weight (kg) 93.6 ± 16.2 86.6 ± 24.2 ns Height (cm) 176.1 ± 10 174 ± 8.8 ns Duration of CHF (years) 5.3 ± 2.6 6.0 ± 5.2 ns Duration of 2DM (years) 7.2 ± 5.8 6.9 ± 4.4 ns LVEF (%) 34.1 ± 9.8 34.8 ± 9.1 ns Etiology of CHF (IHD/DCM/HT) $8/1/1$ $4/4/2$ ns NYHA class (II/III) $5/5$ $3/7$ ns Chronic atrial fibrillation (n) 5 3 ns Beta blockers (n) 9 9 ns Diuretics (n) 9 9 ns Digitalis (n) 2 5 ns Insulin (n) 5 3 ns Acetyl-salicylic acid (n) 5 8 ns Acetyl-salicylic ac				
Sex (F/M) $2/8$ $2/8$ $2/8$ ns Weight (kg) 93.6 ± 16.2 86.6 ± 24.2 ns Height (cm) 176.1 ± 10 174 ± 8.8 ns Duration of CHF (years) 5.3 ± 2.6 6.0 ± 5.2 ns Duration of 2DM (years) 7.2 ± 5.8 6.9 ± 4.4 ns LVEF (%) 34.1 ± 9.8 34.8 ± 9.1 ns Etiology of CHF (IHD/DCM/HT) $8/1/1$ $4/4/2$ ns NYHA class (II/III) $5/5$ $3/7$ ns Chronic atrial fibrillation (n) 5 3 ns Beta blockers (n) 9 8 ns ACE-inhibitors (n) 9 9 ns Diuretics (n) 9 9 ns Insulin (n) 5 3 ns Anti diabetics (n) 5 8 ns Acetyl-salicylic acid (n) 5 8 ns	Variables			P value
Weight (kg) 93.6 ± 16.2 86.6 ± 24.2 ns Height (cm) 176.1 ± 10 174 ± 8.8 ns Duration of CHF (years) 5.3 ± 2.6 6.0 ± 5.2 ns Duration of 2DM (years) 7.2 ± 5.8 6.9 ± 4.4 ns LVEF (%) 34.1 ± 9.8 34.8 ± 9.1 ns Etiology of CHF (IHD/DCM/HT) $8/1/1$ $4/4/2$ ns NYHA class (II/III) $5/5$ $3/7$ ns Chronic atrial fibrillation (n) 5 3 ns Beta blockers (n) 9 9 ns ACE-inhibitors (n) 8 9 ns Diuretics (n) 9 9 ns Digitalis (n) 2 5 ns Insulin (n) 5 8 ns Acetyl-salicylic acid (n) 5 8 ns	Age (years)	65.8 ± 5.8	69 ± 8.2	ns
Height (cm) 176.1 ± 10 174 ± 8.8 ns Duration of CHF (years) 5.3 ± 2.6 6.0 ± 5.2 ns Duration of 2DM (years) 7.2 ± 5.8 6.9 ± 4.4 ns LVEF (%) 34.1 ± 9.8 34.8 ± 9.1 ns Etiology of CHF (IHD/DCM/HT) $8/1/1$ $4/4/2$ ns NYHA class (II/III) $5/5$ $3/7$ ns Chronic atrial fibrillation (n) 5 3 ns Beta blockers (n) 9 8 ns ACE-inhibitors (n) 8 9 ns Diuretics (n) 9 9 ns Digitalis (n) 2 5 ns Insulin (n) 5 3 ns Anti diabetics (n) 5 8 ns Acetyl-salicylic acid (n) 5 8 ns	Sex (F/M)	2/8	2/8	ns
Duration of CHF (years) 5.3 ± 2.6 6.0 ± 5.2 ns Duration of 2DM (years) 7.2 ± 5.8 6.9 ± 4.4 ns LVEF (%) 34.1 ± 9.8 34.8 ± 9.1 ns Etiology of CHF (IHD/DCM/HT) $8/1/1$ $4/4/2$ ns NYHA class (II/III) $5/5$ $3/7$ ns Chronic atrial fibrillation (n) 5 3 ns Beta blockers (n) 9 8 ns ACE-inhibitors (n) 9 9 ns Diuretics (n) 9 9 ns Digitalis (n) 2 5 ns Insulin (n) 5 3 ns Anti diabetics (n) 5 8 ns Acetyl-salicylic acid (n) 5 8 ns	Weight (kg)	93.6 ± 16.2	86.6 ± 24.2	ns
Duration of 2DM (years) 7.2 ± 5.8 6.9 ± 4.4 ns LVEF (%) 34.1 ± 9.8 34.8 ± 9.1 ns Etiology of CHF (IHD/DCM/HT) $8/1/1$ $4/4/2$ ns NYHA class (II/III) $5/5$ $3/7$ ns Chronic atrial fibrillation (n) 5 3 ns Beta blockers (n) 9 8 ns ACE-inhibitors (n) 8 9 ns Diuretics (n) 9 9 ns Digitalis (n) 2 5 ns Insulin (n) 5 3 ns Anti diabetics (n) 5 8 ns Acetyl-salicylic acid (n) 5 8 ns	Height (cm)	176.1 ± 10	174 ± 8.8	ns
(years) 7.2 ± 5.8 6.9 ± 4.4 ns LVEF (%) 34.1 ± 9.8 34.8 ± 9.1 ns Etiology of CHF (IHD/DCM/HT) $8/1/1$ $4/4/2$ ns NYHA class (II/III) $5/5$ $3/7$ ns Chronic atrial fibrillation (n) 5 3 ns Beta blockers (n) 9 8 ns ACE-inhibitors (n) 8 9 ns Diuretics (n) 9 9 ns Digitalis (n) 2 5 ns Insulin (n) 5 3 ns Anti diabetics (n) 5 8 ns Acetyl-salicylic acid (n) 5 8 ns	Duration of CHF (years)	5.3 ± 2.6	6.0 ± 5.2	ns
Etiology of CHF (IHD/DCM/HT) $8/1/1$ $4/4/2$ nsNYHA class (II/III) $5/5$ $3/7$ nsChronic atrial fibrillation (n) 5 3 nsBeta blockers (n) 9 8 nsACE-inhibitors (n) 8 9 nsDiuretics (n) 9 9 nsDigitalis (n) 2 5 nsInsulin (n) 5 3 nsAnti diabetics (n) 5 8 nsAcetyl-salicylic acid (n) 5 8 ns	2 41411011 01 22 111	7.2 ± 5.8	6.9 ± 4.4	ns
(IHD/DCM/HT) $8/1/1$ $4/4/2$ nsNYHA class (II/III) $5/5$ $3/7$ nsChronic atrial fibrillation (n) 5 3 nsBeta blockers (n) 9 8 nsACE-inhibitors (n) 8 9 nsDiuretics (n) 9 9 nsDigitalis (n) 2 5 nsInsulin (n) 5 3 nsAnti diabetics (n) 5 8 nsAcetyl-salicylic acid (n) 5 8 ns	LVEF (%)	34.1 ± 9.8 34.8 ± 9		ns
Chronic atrial fibrillation (n) 53nsBeta blockers (n) 98nsACE-inhibitors (n) 89nsDiuretics (n) 99nsDigitalis (n) 25nsInsulin (n) 53nsAnti diabetics (n) 58nsAcetyl-salicylic acid (n) 58ns		8/1/1	1/1 4/4/2	
fibrillation (n) 5 3 ns Beta blockers (n) 9 8 ns ACE-inhibitors (n) 8 9 ns Diuretics (n) 9 9 ns Digitalis (n) 2 5 ns Insulin (n) 5 3 ns Anti diabetics (n) 5 8 ns Acetyl-salicylic acid (n) 5 8 ns	NYHA class (II/III)	5/5 3/7		ns
ACE-inhibitors (n) 89nsDiuretics (n) 99nsDigitalis (n) 25nsInsulin (n) 53nsAnti diabetics (n) 58nsAcetyl-salicylic acid (n) 58ns		5	3	ns
Diuretics (n) 99nsDigitalis (n) 25nsInsulin (n) 53nsAnti diabetics (n) 58nsAcetyl-salicylic acid (n) 58ns	Beta blockers (n)	9	8	ns
Digitalis (n) 25nsInsulin (n) 53nsAnti diabetics (n) 58nsAcetyl-salicylic acid (n) 58ns	ACE-inhibitors (n)	8	9	ns
Insulin (n) 53nsAnti diabetics (n) 58nsAcetyl-salicylic acid (n) 58ns	Diuretics (n)	9	9	ns
Anti diabetics (n) 5 8 ns Acetyl-salicylic acid (n) 5 8 ns	Digitalis (n)	2	5	ns
Acetyl-salicylic acid (n) 5 8 ns	Insulin (n)	5	3	ns
·	Anti diabetics (n)	5	8	ns
Warfarin (n) 5 3 ns	Acetyl-salicylic acid (n)	5	8	ns
	Warfarin (n)	5	3	ns

F/M: female and male, LVEF: left ventricular ejection fraction, NYHA: New York Heart Association classification, IHD: ischemic heart disease, DCM: dilated cardiomyopathy, HT: hypertension, ACE: angiotensin converting enzyme, *n*: number, ns: not significant.

2.3.3. Muscle Strength and Endurance. For measurement of isometric and isotonic strength and isotonic endurance the Biodex III (Biodex medical systems, New York, USA) was used. The test was preceded by a 5-minute warmup on a test bicycle. The subjects sat with a hip angle of 90°, and the right leg was attached to the lever arm of the dynamometer. Isometric knee extension strength was measured at a 60° knee angle. Isokinetic concentric strength was measured at 60°/s and at 180°/s for knee extensors. Isokinetic endurance was evaluated as the reduction of torque (in percent) between the first and the last three extensions in a series of 50 maximal contractions with an angle of 180°/s. Handgrip strength, the maximum grip force, and the mean value of the 10-second sustained grip was assessed by Grippit (AB Detector, Göteborg, Sweden). Clinical endurance tests, that is, unilateral isotonic heel-lift, bilateral isometric shoulder abduction and unilateral isotonic shoulder flexion were also measured. The test procedures have been described previously [17].

2.3.4. Quality of Life. Health-related quality of life was measured using the Medical Outcome Short Form—36 (SF-36) [19] and disease-specific quality of life with the Minnesota living with heart failure questionnaire (LHFQ) [20]. Hospital




FIGURE 1: The inclusion process of patients.

anxiety and depression scale (HAD) was used to assess the level of anxiety and depression [21].

- 2.3.5. Metabolic Function. Venous blood samples for assessing plasma glucose, HbA1c, serum insulin, serum C-peptide, and serum lipids were taken before and after the intervention period after an overnight fast and analysed according to the European Accreditation system [22].
- 2.3.6. Training Programme. The training programme comprised 45-minute sessions in a heated pool (33°-34°C), three times a week over an eight-week period. The patients trained as a group following a low-to-moderate exercise level, that is, 40 to 75% of maximal heart rate reserve (HRR). The basis posture was standing with water just below neck level. The programme focused on peripheral muscle training but central circulatory exercises were also included as earlier described [17]. The control group was instructed to live their life as normal for eight weeks and was not allowed to increase their habitual physical activity during this period.
- 2.3.7. Statistics. The SPSS 12.0 for Windows (Chicago, IL, USA) was used to analyse the data.

Ratio and interval data are given as mean (± 1 SD or 95% CI) and ordinal data as median and range. Wilcoxon-matched pairs signed rank sum test was used for comparisons of paired observations within each study group. The Mann Whitney U-test was used to assess differences between groups. Nominal data between groups was compared by Chi-squared test or Fisher's exact test. A P value ≤ 0.05 was considered significant. A per-protocol design was used on all data.

3. Results

Aquatic exercise was well tolerated by the patients and no adverse events occurred during the aquatic exercise. Two patients in the training group were withdrawn, due to a peripheral ulcer caused by new shoes, increased symptoms of CHF, respectively. One patient in the control group was withdrawn, due to family problems. The average adherence (total number of attended sessions) was 92%. HRR during training ranged between 40% and 60% during peripheral muscle training exercises and between 55% and 75% during the aerobic exercises. In the training group two patients needed to reduce their insulin and one to take away the oral antidiabetics due to hypoglycaemia.

3.1. Exercise Capacity and Muscle Function. Physical performance was significantly improved in the training group




FIGURE 2: Work rate (a), peak oxygen uptake VO_{2peak} (b), and distance walked (c) in six minute walk test before \square (n = 10 and 10) and after \blacksquare (n = 8 and 9) eight weeks of aquatic exercise.

compared with the control group, regarding work rate, VO_{2peak} (P < 0.001), and walking capacity (P = 0.01) (Figure 2(a)–2(c)). There were no significant differences in knee extension regarding isometric strength, isotonic strength 60°/s, or isotonic endurance, neither in handgrip strength or endurance. However, a significant increase in isokinetic strength 180°/s (P < 0.001), isotonic heel lift (P = 0.01), shoulder flexion (P < 0.05), and isometric shoulder abduction (P < 0.001) was found in the training group after aquatic exercise (Table 2).

3.2. Metabolic Function. Hba1c decreased during aquatic exercise, but there was no significant improvement in fasting plasma glucose, insulin, c-peptide, or blood lipids after eight weeks of training (Table 3).

3.3. Health Related Quality of Life. Compared to a Swedish reference population [23], our patients with CHF and 2DM had lower SF-36 scores in all domains except for bodily pain, Figure 3(a). There was a significant difference in vitality scoring after aquatic exercise, whereas other domains were unchanged, Figure 3(b). Disease specific quality of life and

grade of anxiety was unchanged in both groups after the intervention period, Table 4.

4. Discussion

This is the first study to show that aquatic exercise could be used as an effective tool to improve physical function in patients with the combination of CHF and 2DM. Further, the study confirms the results of our previous study with warm water training in elderly patients, supporting that this training is safe for patients with CHF.

4.1. Exercise Performance. A number of studies have demonstrated that exercise training on land, aerobic and resistance exercise improve function in patients with either CHF or with 2DM [15, 16]. VO_{2peak} is an important prognostic marker in these patients [24, 25] and it is significantly more reduced in patients with a combination of 2DM and CHF, than in patients with only one of the diseases [26]. It was therefore an important finding in this study that aquatic exercise was associated with a significant improvement in VO_{2peak} . Improved general performance was also shown as an increase in work rate and walking capacity. The physiological

Table 2: Muscle function before and after aquatic exercise in patients with chronic heart failure and type 2 diabetes mellitus.

Knee extension in Biodex III. Isokinetic		Before $(n = 10/10)$	After $(n = 8/9)$	P value within the group	<i>P</i> value versus the control group	
Peak torque (60°s Nm) right leg		122 ± 41	127 ± 34	ns	ns	
		102 ± 30	98 ± 32	ns	115	
Peak torque (180°s Nm) right leg	T	88 ± 28	119 ± 54	0.02	< 0.001	
reak torque (100 s Will) right leg	С	66 ± 22	64 ± 24	ns	<0.001	
Endurance decline in %, left leg	T	46 ± 17	44 ± 13	ns	ns	
Enquiance decline in 70, left leg		51 ± 14	52 ± 16	ns	113	
Isometric						
Peak torque	T	136 ± 41	136 ± 40	ns	ns	
60° (N) right leg	C	109 ± 37	101 ± 32	ns	113	
Hand strength						
Peak force (N)		342 ± 121	385 ± 106	ns	ns	
Right hand	C	248 ± 82	221 ± 62	0.04	113	
Peak force 10 s (N)		289 ± 108	323 ± 89	ns	ns	
Right hand	C	207 ± 77	187 ± 62	ns	113	
Clinical endurance tests						
Heel lift (n.o)	T	14 ± 7	18 ± 6	0.01	0.01	
ricer nit (ii.o)	С	14 ± 4	14 ± 5	ns	0.01	
Shoulder flexion (n.o)	T	$26 \pm 11^*$	36 ± 12	0.02	0.03	
	C	17 ± 8	17 ± 28	ns	0.03	
Shoulder abduction (s)	T	75 ± 25	89 ± 27	0.01	< 0.001	
onomider abduction (8)	С	64 ± 26	56 ± 22	0.03	\0.001	

T: Training group, C: control group, ns: not significant, n.o.: number of, $*: P \le 0.05$ at baseline between training and control group.

Table 3: Metabolic function before and after aquatic exercise in patients with chronic heart failure and type 2 diabetes mellitus.

Variables		Before $(n = 10/10)$	After $(n = 8/9)$	P value within the group	<i>P</i> value versus the control group	
Hba1c (%)	Т	7.9 ± 2.9	7.2 ± 0.9	0.01	ns	
	С	6.9 ± 2.0	6.7 ± 3.2	ns	115	
P-Fasting glucos (mmol/L)	T	10.2 ± 2.9	9.3 ± 2.6	ns	ns	
	С	7.8 ± 3.3	6.9 ± 2.0	ns	115	
S-Insulin (mU/L)	T	20 ± 5.7	20.1 ± 11.5	ns	ns	
	С	19.2 ± 14.9	16.1 ± 14.0	ns	115	
S-C-peptide (nmol/L)	T	0.8 ± 0.4	1.1 ± 0.5	ns	ns	
	С	1.0 ± 0.9	1.4 ± 1.5	ns	115	
S-Triglycerides (mmol/L)	T	2.4 ± 3.4	2.2 ± 2.1	ns	ns	
	С	1.9 ± 1.0	1.6 ± 0.8	ns	115	
S-Cholesterol (mmol/L)	T	4.2 ± 1.0	4.3 ± 0.9	ns	ns	
	С	4.2 ± 1.1	4.1 ± 0.5	ns	115	

P: plasma, S: serum, T: training group, C: control group.

reason for this improvement was not investigated, but others have shown that exercise in the two diseases separately results in cardiac and peripheral muscle function enhancement which improves cardiac output and arteriovenous oxygen difference. Elevated peripheral resistance and poor endothelial function are factors that might contribute to

reduced exercise capacity; however it could be enhanced by physical training [15, 16]. Immersion in warm water results in immediate improvement in cardiac function, probably mediated by peripheral vasodilation and unloading of left ventricular function [27, 28]. Whether such effects would be more beneficial during long-term treatment, compared with




FIGURE 3: (a) Scores of SF-36 in all patients with chronic heart failure and type 2 diabetes mellitus, \blacksquare , (n = 20) compared to a Swedish healthy reference population $-\lozenge$ -. (b) Change in SF-36 after aquatic exercise, training group, \blacksquare , (n = 8) control group, \square , $(n = 9)^*$, P = 0.05.

Table 4: No significant changes in disease specific quality of life and grade of anxiety and depression occurred after eight weeks of aquatic exercise.

LHFQ		Before $(n = 10/10)$	After $(n = 8/9)$	HAD	Before (n = 10/10)	After $(n = 8/9)$
Total score	T	48 ± 22	43 ± 15	Anxiety	5.1 ± 4.8	5.4 ± 3.7
	С	35 ± 13	35 ± 16		3.1 ± 1.8	3.5 ± 3.0
Physical dimension	T	22 ± 14	16 ± 8	Depression	3.5 ± 3.2	3.6 ± 2.3
	С	19 ± 11	20 ± 13		4.2 ± 2.7	4.9 ± 3.7
Emotional dimension	T	10 ± 8	7 ± 6			
	С	5 ± 4	5 ± 4			

LHFQ: Minnesota living with heart failure questionnaire HAD: hospital anxiety and depression scale. T: Training group, C: control group.

training on land, would need further studies comparing the two exercise regimens.

4.2. Muscular Performance. Isokinetic strength in knee extensors was merely significantly improved at 180°/s and not in isokinetic strength at 60°/s or in isokinetic endurance and isometric strength. We have previously been hypothesised that an absent improvement in knee muscle function during aquatic exercise is due to the difficulty to gain enough resistance for this large muscle group in water [17]. However, the sensitivity of the test does also have large impact of the test results after training. Studies have shown that isotonic knee extensor training did not result in isokinetic knee extensor improvement [29, 30]. The increment in knee extension at 180°/s might be due to an enhanced neural adaptation since this test mirrors the ability to develop power [31, 32]. It seems less likely that this improvement should be attributable to an increase in the amount of type II fibres, after a relatively short endurance training of eight weeks. Aquatic exercise resulted also in increased isometric and isotonic muscle endurance measured by clinical endurance tests. These tests were performed exactly the way as it was trained. Specific adaptations in skeletal muscle after exercise seem to benefit patients with 2DM since the active muscle tissue reveals a higher metabolic rate in glucose metabolism

[15]. An important finding in this study was that the training maintained and improved endurance in both upper and lower body muscle groups, which is important for older people to prevent falls and to accomplish daily tasks of living requiring both static and dynamic efforts [33].

4.3. Metabolic Control. No specific advice concerning diet or diabetic treatment was given during this study. Diabetic therapy was supplied by the patient's ordinary health care and was not part of the study. A positive finding was the decrease in HbA1c after training. However, other markers of metabolic control did not change. It was not the scope of this study to investigate insulin resistance, and others have shown signs of decreased insulin resistance after exercise in 2DM [34] however, the effect of training is unclear in CHF [35]. We could not confirm that immersion in warm water solely could enhance metabolic function in patients with 2DM, as shown by Hooper [36].

4.4. Quality of Life Measurements. The size of the population in this study was inadequate to show unequivocal changes in quality of life. Of the instruments used, only an index in SF-36, vitality increased after aquatic exercise. Since the level of anxiety and depression was low among most of our patients at baseline no effect was seen in HAD scores.

4.5. Aquatic Exercise. Aquatic exercise enables a combination of aerobic and resistance exercises and is especially suitable for patients with advanced age, obesity, peripheral neuropathy, orthopaedic problems, or other comorbidity that hampers exercises on land. Due to the buoyancy effect in water weight bearing activities are much more effortless to perform in water [37]. For example, it is more uncomplicated for a patient with peripheral neuropathy to walk in water.

The rate of adherence in this supervised short-term exercise study was high, which is in accordance with several other studies in patients with CHF [17, 38, 39] as well as with 2DM [24]. However, the long-term adherence in nonsupervised exercise has been reported low by others [40, 41]. A "smorgasbord" of physical training regimen to the patient's disposal might enhance the rate of adherence to prescribed exercise.

4.6. Limitations. Similar to many other exercise studies in patients with CHF, our study was performed in a limited number of patients which may restrict external validity. A marked difficulty was to recruit patients that were free from other disabling and complicating disorders like peripheral ulcers, infections, or problems with glycaemic control which are more common in patients with the combination of CHF and 2DM. Further, these patients have a higher morbidity that increases the risk of withdrawal during the study period. In clinical practice, these conditions might temporarily hinder participation in training programmes. However, a temporary stop in the programme should not exclude these patients from the beneficial effects of physical training in the long run.

5. Conclusion

Aquatic exercise is safe and effective to improve physical and metabolic function in patients with the combination of CHF and 2DM. Whether conventional exercise on land is equally effective has not been shown and would need further studies. Training in water is especially beneficial for those patients with other disabilities that obstruct exercises on land.

Acknowledgments

This study was supported by the Swedish Heart and Lung Association and the FRF foundation.

References

- [1] L. Soläng, K. Malmberg, and L. Rydén, "Diabetes mellitus and congestive heart failure. Further knowledge needed," *European Heart Journal*, vol. 20, no. 11, pp. 789–795, 1999.
- [2] J. G. F. Cleland, K. Swedberg, F. Follath et al., "The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis," *European Heart Journal*, vol. 24, no. 5, pp. 442–463, 2003.
- [3] C. M. Clark Jr. and R. C. Perry, "Type 2 diabetes and macrovascular disease: epidemiology and etiology," *American Heart Journal*, vol. 138, no. 5, pp. S330–S333, 1999.

- [4] R. O. Bonow and M. Gheorghiade, "The diabetes epidemic: a national and global crisis," *American Journal of Medicine*, vol. 116, no. 5, supplement, pp. 2S–10S, 2004.
- [5] J. W. Swan, C. Walton, I. F. Godsland, A. L. Clark, A. J. S. Coat, and M. F. Oliver, "Insulin resistance in chronic heart failure," *European Heart Journal*, vol. 15, no. 11, pp. 1528–1532, 1994.
- [6] J. A. Franciosa, M. Park, and T. B. Levine, "Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure," *American Journal of Cardiology*, vol. 47, no. 1, pp. 33–39, 1981.
- [7] J. G. Regensteiner, T. A. Bauer, J. E. B. Reusch et al., "Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus," *Journal of Applied Physiology*, vol. 85, no. 1, pp. 310–317, 1998.
- [8] A. L. Clark, P. A. Poole-Wilson, and A. J. S. Coats, "Exercise limitation in chronic heart failure: central role of the periphery," *Journal of the American College of Cardiology*, vol. 28, no. 5, pp. 1092–1102, 1996.
- [9] P. Marin, B. Andersson, M. Krotkiewski, and P. Bjorntorp, "Muscle fiber composition and capillary density in women and men with NIDDM," *Diabetes Care*, vol. 17, no. 5, pp. 382– 386, 1994.
- [10] A. Cohen-Solal, F. Beauvais, and J. Y. Tabet, "Physiology of the abnormal response of heart failure patients to exercise," *Current Cardiology Reports*, vol. 6, no. 3, pp. 176–181, 2004.
- [11] B. Guerci, A. Kearney-Schwartz, P. Böhme, F. Zannad, and P. Drouin, "Endothelial dysfunction and type 2 diabetes: part 1: physiology and methods for exploring the endothelial function," *Diabetes and Metabolism*, vol. 27, no. 4, pp. 425– 434, 2001.
- [12] E. Miche, G. Herrmann, M. Nowak et al., "Effect of an exercise training program on endothelial dysfunction in diabetic and non-diabetic patients with severe chronic heart failure," *Clinical Research in Cardiology*, vol. 95, no. 1, supplement, pp. I/117–I/124, 2006.
- [13] J. F. Donie, "The relationship between diabetes and depression: improving the effectiveness of case management interventions," *Lippincott's Case Management*, vol. 9, no. 4, pp. 177–183, 2004.
- [14] E. P. Havranek, K. M. Mcgovern, J. Weinberger, A. Brocato, B. D. Lowes, and W. T. Abraham, "Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure," *Journal of Cardiac Failure*, vol. 5, no. 2, pp. 85–91, 1999.
- [15] A. Albright, M. Franz, G. Hornsby et al., "American College of Sports Medicine position stand. Exercise and type 2 diabetes," *Medicine & Science in Sports & Exercise*, vol. 32, no. 7, pp. 1345–1360, 2000.
- [16] I. L. Piña, C. S. Apstein, G. J. Balady et al., "Exercise and heart failure: a statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention," *Circulation*, vol. 107, no. 8, pp. 1210–1225, 2003.
- [17] A. Cider, M. Schaufelberger, K. S. Sunnerhagen, and B. Andersson, "Hydrotherapy—a new approach to improve function in the older patient with chronic heart failure," *European Journal of Heart Failure*, vol. 5, no. 4, pp. 527–535, 2003.
- [18] G. H. Guyatt, M. J. Sullivan, and P. J. Thompson, "The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure," *Canadian Medical Association Journal*, vol. 132, no. 8, pp. 919–921, 1985.
- [19] J. E. Ware Jr. and C. D. Sherbourne, "The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection," *Medical Care*, vol. 30, no. 6, pp. 473–483, 1992.

- [20] T. S. Rector, S. H. Kubo, and J. N. Cohn, "Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo," *American Journal of Cardiology*, vol. 71, no. 12, pp. 1106–1107, 1993.
- [21] A. S. Zigmond and R. P. Snaith, "The hospital anxiety and depression scale," *Acta Psychiatrica Scandinavica*, vol. 67, no. 6, pp. 361–370, 1983.
- [22] European co-operation for Accreditation. (Internet) (cited 20120327) Available from: http://www.european-accreditation.org/content/ea/europNetwork.htm.
- [23] L. O. Persson, J. Karlsson, C. Bengtsson, B. Steen, and M. Sullivan, "The Swedish SF-36 Health Survey II. Evaluation of clinical validity: results from population studies of elderly and women in Gothenborg," *Journal of Clinical Epidemiology*, vol. 51, no. 11, pp. 1095–1103, 1998.
- [24] N. G. Boulé, G. P. Kenny, E. Haddad, G. A. Wells, and R. J. Sigal, "Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus," *Diabetologia*, vol. 46, no. 8, pp. 1071–1081, 2003.
- [25] J. Myers, L. Gullestad, R. Vagelos et al., "Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure," Annals of Internal Medicine, vol. 129, no. 4, pp. 286–293, 1998.
- [26] M. Guazzi, R. Brambilla, G. Pontone, P. Agostoni, and M. D. Guazzi, "Effect of non-insulin-dependent diabetes mellitus on pulmonary function and exercise tolerance in chronic congestive heart failure," *American Journal of Cardiology*, vol. 89, no. 2, pp. 191–197, 2002.
- [27] A. Gabrielsen, V. B. Sørensen, B. Pump et al., "Cardiovascular and neuroendocrine responses to water immersion in compensated heart failure," *American Journal of Physiology*, vol. 279, no. 4, pp. H1931–H1940, 2000.
- [28] K. Meyer and J. Bücking, "Exercise in heart failure: should aqua therapy swimming be allowed?" *Medicine and Science in Sports and Exercise*, vol. 36, no. 12, pp. 2017–2023, 2004.
- [29] J. Augustsson, A. Esko, R. Thomeé, and U. Svantesson, "Weight training of the thigh muscles using closed vs. open kinetic chain exercises: a comparison of performance enhancement," *Journal of Orthopaedic and Sports Physical Therapy*, vol. 27, no. 1, pp. 3–8, 1998.
- [30] G. G. Sleivert, R. D. Backus, and H. A. Wenger, "The influence of a strength-sprint training sequence on multi-joint power output," *Medicine and Science in Sports and Exercise*, vol. 27, no. 12, pp. 1655–1665, 1995.
- [31] A. Ferri, G. Scaglioni, M. Pousson, P. Capodaglio, J. Van Hoecke, and M. V. Narici, "Strength and power changes of the human plantar flexors and knee extensors in response to resistance training in old age," *Acta Physiologica Scandinavica*, vol. 177, no. 1, pp. 69–78, 2003.
- [32] D. R. Taaffe and R. Marcus, "Dynamic muscle strength alterations to detraining and retraining in elderly men," *Clinical Physiology*, vol. 17, no. 3, pp. 311–324, 1997.
- [33] M. L. Pollock, B. A. Franklin, G. J. Balady et al., "Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association," *Circulation*, vol. 101, no. 7, pp. 828–833, 2000.
- [34] S. P. Tokmakidis, C. E. Zois, K. A. Volaklis, K. Kotsa, and A. M. Touvra, "The effects of a combined strength and aerobic exercise program on glucose control and insulin action in women with type 2 diabetes," *European Journal of Applied Physiology*, vol. 92, no. 4-5, pp. 437–442, 2004.

- [35] L. W. E. Sabelis, P. J. Senden, B. C. M. Te Boekkorst et al., "Does physical training increase insulin sensitivity in chronic heart failure patients?" *Clinical Science*, vol. 106, no. 5, pp. 459–466, 2004
- [36] P. L. Hooper, "Hot-tub therapy for type 2 diabetes mellitus," The New England Journal of Medicine, vol. 341, no. 12, pp. 924– 925, 1999.
- [37] S. B. Burns and J. L. Burns, "Hydrotherapy," *Journal of Alternative and Complementary Medicine*, vol. 3, no. 2, pp. 105–107, 1997.
- [38] R. Hambrecht, J. Neibauer, E. Fiehn et al., "Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles," *Journal of the American College of Cardiology*, vol. 25, no. 6, pp. 1239–1249, 1995.
- [39] R. A. Tyni-Lenné, K. E. Dencker, A. L. Gordon, E. V. Jansson, and C. H. Sylvén, "Comprehensive local muscle training increases aerobic working capacity and quality of life and decreases neurohormonal activation in patients with chronic heart failure," *European Journal of Heart Failure*, vol. 3, no. 1, pp. 47–52, 2001.
- [40] T. Ishii, T. Yamakita, T. Sato, S. Tanaka, and S. Fujii, "Resistance training improves insulin sensitivity in NIDDM subjects without altering maximal oxygen uptake," *Diabetes Care*, vol. 21, no. 8, pp. 1353–1355, 1998.
- [41] K. J. Stewart, "Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health," *Journal of* the American Medical Association, vol. 288, no. 13, pp. 1622– 1631, 2002.